Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Lymphoma, Non-Hodgkin 3Melanoma 2Lymphoma, Mantle-Cell 2Lymphoma 2Waldenstrom Macroglobulinemia 1Neoplasms 1Mycosis Fungoides 1Mycoses 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Ipilimumab 98pembrolizumab 84Nivolumab 82aldesleukin 51Cyclophosphamide 49Interleukin-2 38fludarabine phosphate 31Vemurafenib 31Dacarbazine 31dabrafenib 29trametinib 28Temozolomide 26fludarabine 25CTLA-4 Antigen 18Bevacizumab 18Radiosurgery 15Paclitaxel 15Carboplatin 14encorafenib 13binimetinib 13Introns 13talimogene laherparepvec 12Radiotherapy 12Interferon alpha-2 12spartalizumab 11cobimetinib 10atezolizumab 10sargramostim 9peginterferon alfa-2b 9montanide ISA 51 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Melanoma × ProMune × Clear all
NCT00145158 2022-10-10

Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma

Ludwig Institute for Cancer Research

Phase 1/2 Terminated
23 enrolled 8 charts
Dermatologic

Melanoma

NCT00145145 2022-10-07

Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic Melanoma

Ludwig Institute for Cancer Research

Phase 1/2 Terminated
1 enrolled 4 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡